In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022
European Journal of Clinical Microbiology & Infectious Diseases · 2025-03 · 44 (3) · 571-585
DOI: 10.1007/s10096-024-04994-6 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Clinical Microbiology & Infectious Diseases, online erschienen am 20.12.2024. Verfasst von Christophe Le Terrier und 6 weiteren Autor:innen. Beteiligte Einrichtung: Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, Fribour…. Hauptthemen laut MEDLINE: beta-Lactamase Inhibitors, Anti-Bacterial Agents, Pseudomonas, Pseudomonas Infections. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Fribourg.
Abstract (Originalsprache)
To evaluate the in-vitro activity of the novel commercially-available drugs, including meropenem-vaborbactam (MEV), ceftazidime-avibactam (CZA), ceftolozane-tazobactam (C/T), imipenem-relebactam (IPR) as well as cefiderocol (FDC), against carbapenem-resistant Pseudomonas spp. (CRP) isolates. All CRP isolates collected at the Swiss National Reference Laboratory (NARA) over the year 2022 ( n = 170) have been included. Most of these isolates ( n = 121) were non-carbapenemase producers. Among the 49 carbapenemase producers, 47 isolates produced metallo-β-lactamases (MBL) including NDM-1 ( n = 11), VIM-like ( n = 28), IMP-like ( n = 7), and both NDM-1 and VIM-2 ( n = 1) and two isolates produced the class A carbapenemase GES-5. Susceptibility testing was determined by broth microdilution method (BMD), or disk diffusion test, and results interpreted following EUCAST guidelines. The susceptibility rates for MEV, CZA, C/T and IPR were found to be 41%, 45%, 59% and 58%, respectively, for the whole set of isolates tested. Among non-carbapenemase producers, susceptibility rates for these β-lactam/β-lactamase inhibitors (BL/BLI) combinations were higher, determined at 55%, 61%, 83%, and 82%, respectively. The overall susceptibility of carbapenemase-producing Pseudomonas spp. to novel BL/BLI was relatively low, while 80% of these isolates demonstrated susceptibility to FDC, with a similar proportion (79%) observed among MBL producers. A total of 10 MBL-producing isolates (6%), mainly NDM-1, were found to exhibit resistance to all drugs tested, with the exception of colistin. FDC exhibited an excellent in-vitro activity against this collection of CRP recovered from Switzerland in 2022, including MBL producers. The new BL/BLI combinations displayed significant activity against non-carbapenemase CRP, with IPR and C/T showing the highest susceptibility rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, Fribourg, CH-1700, Switzerland.
- Division of Intensive Care Unit, University Hospitals of Geneva, Geneva, Switzerland.
- Emergency Department, Fribourg Hospitals, Fribourg, Switzerland.
- Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland.
- Medical and Molecular Microbiology Unit, Department of Medicine, Faculty of Science and Medicine, University of Fribourg, Chemin du Musée 18, Fribourg, CH-1700, Switzerland. laurent.poirel@unifr.ch.
- Swiss National Reference Center for Emerging Antibiotic Resistance (NARA), University of Fribourg, Fribourg, Switzerland. laurent.poirel@unifr.ch.
Förderung
- University of Fribourg
Zitieren
APA
Le Terrier, C., Bouvier, M., Kerbol, A., Dell'Acqua, C., Nara Network members, Nordmann, P., & Poirel, L. (2025). In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022. European Journal of Clinical Microbiology & Infectious Diseases, 44(3), 571-585. https://doi.org/10.1007/s10096-024-04994-6
Vancouver
Le Terrier C, Bouvier M, Kerbol A, Dell'Acqua C, Nara Network members, Nordmann P, et al. In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022. European Journal of Clinical Microbiology & Infectious Diseases. 2025;44(3):571-585. doi:10.1007/s10096-024-04994-6
BibTeX
@article{LeTerrier2025,
author = {Le Terrier, Christophe and Bouvier, Maxime and Kerbol, Auriane and Dell'Acqua, Chloé and Nara Network members, Nara Network members and Nordmann, Patrice and Poirel, Laurent},
title = {In-vitro activity of the novel β-lactam/β-lactamase inhibitor combinations and cefiderocol against carbapenem-resistant Pseudomonas spp. clinical isolates collected in Switzerland in 2022},
journal = {European Journal of Clinical Microbiology & Infectious Diseases},
year = {2025},
volume = {44},
number = {3},
pages = {571--585},
doi = {10.1007/s10096-024-04994-6}
}
EUVIMED